Acquisition Biotech China Finance Healthcare Investment New York Pacific Pharmaceutical Technology Venture Capital
In a significant development within the pharmaceutical industry, Lynk Pharmaceuticals Co., Ltd. (referred to as ‘Lynk Pharmaceuticals’) and Formation Bio have finalized an exclusive agreement involving the rights to LNK01006, a cutting-edge central nervous system (CNS)-penetrant highly selective TYK2 inhibitor. Formation Bio’s new subsidiary, Bleecker Bio, will spearhead the asset’s development and licensing, excluding Greater China, expanding its international footprint. LNK01006 recently obtained FDA clearance to commence its inaugural human studies in the US, signifying a major milestone. Formation Bio’s ambitious strategy includes launching a Phase 1 study in the first half of 2026, reflecting its commitment to diversifying its…
News Timeline:
Track the development of this news story across the Internet.